NGNE Neurogene Inc.

NASDAQ
$23.30

Neurogene Inc. (NGNE) is expected to report earnings on February 8, 2027, before the market open. The consensus earnings estimate is a loss of $1.29 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.3% since its last earnings release on November 9, 2026.

Neurogene Inc. Beat Consensus Estimates
Monday, November 9, 2026 · 7:30 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 7:30 AM ET
Earnings Whisper
-
vs ($1.29)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $24.80

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Neurogene Inc.

Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.